BioMark Diagnostics (TSE:BUX) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BioMark Diagnostics has made a significant advancement in breast cancer diagnosis with its liquid biopsy platform capable of predicting estrogen receptor status with 93% accuracy. This breakthrough promises to revolutionize breast cancer diagnosis and treatment, potentially saving lives through earlier diagnoses and personalized treatment options.
For further insights into TSE:BUX stock, check out TipRanks’ Stock Analysis page.